City of Hope is set to present blood cancer cell therapy updates and other targeted regimens at ASH 2026, focusing on clinical progress in outpatient CAR T delivery and next-generation approaches. The program positions the organization to highlight operational learnings as well as efficacy data. The emphasis on outpatient administration is particularly relevant for cell therapy scalability, since hospital-based infrastructure and inpatient monitoring requirements can constrain throughput. ASH presentations typically serve as the first public signal of trial momentum and safety management outside of formal regulatory filings. In addition to CAR T, City of Hope plans to share developments in novel cell therapy platforms and targeted regimens for blood malignancies. Those updates will likely be read alongside ongoing industry efforts to refine patient selection and manage treatment-related toxicities. The immediate industry impact is informational—tracking what evidence is ready to be disclosed at scale. Follow-on attention will likely center on response depth, durability signals, and how protocols translate in routine clinical settings.